Excitatory Amino Acids: Clinical Results with Antagonists Philippa H. · Breaking the Robustness Barrier:

· Breaking the Robustness Barrier: Recent Progress on the Design of Robust Multimodal Systems

Organized by the VLDB Endowment

* Based upon a longitudinal survey of a demographically diverse sample of principal caregivers over a three-year period

Data Reconciliation and Gross Error Detection is the ultimate reference

safety aspects

Excitatory Amino Acids: Clinical Results with Antagonists Philippa H. · Breaking the Robustness Barrier:Glutamate is the major excitatory neurotransmitter in the brain and dysfunction of glutamate transmission is the likely cause of a variety of diseases including neurodegeneration following cerebral ischemia, Huntington's chorea, amyotrophic lateral sclerosis, epilepsy, spasticity, emesis, chronic pain, and schizophrenia. Excitatory amino acid receptor agonists and antagonists are therefore of major interest as potential drugs for central nervous